Roche ‘fast-tracking' weight-loss drug that rivals Wegovy

Core Insights - Roche is accelerating the clinical development of its obesity drug portfolio to bring medications to market faster than expected, with potential availability by 2028 [1][4][7] - Hims & Hers Health Inc. has launched its own injectable weight-loss drugs at a lower price point compared to existing options like Ozempic and Wegovy [2][5] - The global obesity drug market is projected to exceed $100 billion by 2030, with potential growth up to $144 billion as applications expand beyond weight loss [6] Company Developments - Roche is fast-tracking its candidates in the weight-loss drug market, which is currently dominated by Novo Nordisk and Eli Lilly [7][14] - Pfizer is advancing its once-daily weight-loss pill, CT-388, into phase two trials after positive early-stage results, with participants losing significant body weight [10][12][13] Market Overview - The obesity drug market generated $6 billion in sales in 2023, indicating strong demand for weight-loss medications [8] - GLP-1 agonists, including semaglutide and tirzepatide, are key players in the market, known for their effectiveness in managing Type 2 diabetes and promoting weight loss [3][14]